ELD 607
Alternative Names: ELD-607Latest Information Update: 01 Jul 2024
At a glance
- Originator University of North Carolina at Chapel Hill
- Developer Eldec Pharmaceuticals
- Class Anti-infectives; Anti-inflammatories; Peptides
- Mechanism of Action ORAI1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pneumonia
Most Recent Events
- 17 May 2024 Pharmacodynamics data from a preclinical study in Pneumonia presented at the 120th International Conference of the American Thoracic Society (ATS-2024)
- 11 Sep 2023 Eldec Pharmaceuticals receives SBIR (STTR program) grant from NIH for ELD 607 development in Pneumonia
- 11 Sep 2023 Eldec pharmaceuticals files for patent protection with USPTO for Modified peptidomimetics and methods of use in USA